Insulet, a medical device company, has reported positive results from the first feasibility study of its Omnipod Horizon hybrid closed-loop system for the treatment of patients with type 1 diabetes.

The Omnipod Insulin Management System is a continuous insulin delivery system designed to provide continuous subcutaneous insulin infusion (CSII) therapy.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It consists of a pod that stores and delivers insulin, in addition to a personal diabetes manager (PDM) that wirelessly programmes the user's personalised insulin delivery, calculates suggested doses and insulin and has a built-in blood glucose meter.

"The Omnipod hybrid closed-loop system allowed patients to spend comparitively less time in hypoglycemic blood glucose range."

The 36-hour study was conducted in 24 adult patients and involved the use of a modified version of the Omnipod, a Dexcom continuous glucose sensor, and Insulet’s personalised model predictive control algorithm.

The results from the study showed that the Omnipod automated glucose control algorithm performed well, was safe during both day and night and was effective at night with improved fasting glucose and minimal hypoglycemia.

See Also:

The Omnipod hybrid closed-loop system allowed patients to spend comparitively less time in hypoglycemic blood glucose range.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It was also found that patients achieved the target blood glucose control range 69% of the time and maintained the target blood glucose control 90% of the time during the overnight period.

The small, light-weight pod of the Omnipod system is claimed to enable the user to wear it in various locations such as the abdomen, hip, back of upper arm, upper thigh or lower back. It is also said to provide up to three days of non-stop insulin delivery.